Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Ray

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Journal of Oncology Practice|April 20, 2013
A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR reportBrian Chen, John Restaino, LeAnn Norris, et al.
Cancer Medicine|June 22, 2017
Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR)Rachel A Sabol, Virginia Noxon, Oliver Sartor, et al.
The Lancet. Oncology|December 3, 2020
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse ReactionsCharles L Bennett, Martin W Schoen, Shamia Hoque, et al.
Plos One|June 26, 2020
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemiaShamia Hoque, Brian J Chen, Martin W Schoen, et al.
Journal of General Internal Medicine|June 14, 2012
Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR)Charles L Bennett, Karen M Starko, Henrik S Thomsen, et al.
The Lancet. Oncology|December 3, 2014
Regulatory and clinical considerations for biosimilar oncology drugsCharles L Bennett, Brian Chen, Terhi Hermanson, et al.
The Oncologist|February 15, 2021
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse ReactionsCharles L Bennett, Sumimasa Nagai, Andrew C Bennett, et al.
The Journal of Community and Supportive Oncology|March 9, 2016
Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social networkKamaljeet Kaur, Raja Fayad, Arpit Saxena, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal of Oncology Practice|April 20, 2013
A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR reportBrian Chen, John Restaino, LeAnn Norris, et al.
Cancer Medicine|June 22, 2017
Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR)Rachel A Sabol, Virginia Noxon, Oliver Sartor, et al.
The Lancet. Oncology|December 3, 2020
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse ReactionsCharles L Bennett, Martin W Schoen, Shamia Hoque, et al.
Plos One|June 26, 2020
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemiaShamia Hoque, Brian J Chen, Martin W Schoen, et al.
Journal of General Internal Medicine|June 14, 2012
Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR)Charles L Bennett, Karen M Starko, Henrik S Thomsen, et al.
The Lancet. Oncology|December 3, 2014
Regulatory and clinical considerations for biosimilar oncology drugsCharles L Bennett, Brian Chen, Terhi Hermanson, et al.
The Oncologist|February 15, 2021
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse ReactionsCharles L Bennett, Sumimasa Nagai, Andrew C Bennett, et al.
The Journal of Community and Supportive Oncology|March 9, 2016
Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social networkKamaljeet Kaur, Raja Fayad, Arpit Saxena, et al.
Pageof 2